Literature DB >> 16669863

The pharmacokinetics of orbifloxacin in the horse following oral and intravenous administration.

J L Davis1, M G Papich, A Weingarten.   

Abstract

The purpose of this study was to determine the pharmacokinetics and physicochemical characteristics of orbifloxacin in the horse. Six healthy adult horses were administered oral and intravenous orbifloxacin at a dose of 2.5 mg/kg. Plasma samples were collected and analyzed by high-pressure liquid chromatography with ultraviolet detection. Plasma protein binding and lipophilicity were determined in vitro. Following i.v. administration, orbifloxacin had a terminal half-life (t1/2) of 5.08 h and a volume of distribution (V(d(SS))) of 1.58 L/kg. Following oral administration, the average maximum plasma concentration (Cmax) was 1.25 microg/mL with a t1/2 of 3.42 h. Systemic bioavailability was 68.35%. Plasma protein binding was 20.64%. The octanol:water partition coefficient (pH 7.4) was 0.2 +/- 0.11. No adverse reactions were noted during this study. Dosage regimens were determined from the pharmacokinetic-pharmacodynamic parameters established for fluoroquinolone antibiotics. For susceptible bacteria, an oral dose of approximately 5 mg/kg once daily will produce plasma concentrations within the suggested range. This dose is suggested for further studies on the clinical efficacy of orbifloxacin for treatment of susceptible bacterial infections in the horse.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16669863     DOI: 10.1111/j.1365-2885.2006.00737.x

Source DB:  PubMed          Journal:  J Vet Pharmacol Ther        ISSN: 0140-7783            Impact factor:   1.786


  2 in total

1.  Integration of pharmacokinetic and pharmacodynamic indices of orbifloxacin in beagle dogs after a single intravenous and intramuscular administration.

Authors:  Elias Gebru; Joong-Su Lee; Zhi-Qiang Chang; Mi-Hyun Hwang; Henrique Cheng; Seung-Chun Park
Journal:  Antimicrob Agents Chemother       Date:  2009-04-27       Impact factor: 5.191

2.  Development and validation of a microbiological agar assay for determination of orbifloxacin in pharmaceutical preparations.

Authors:  Edith C L Cazedey; Hérida R N Salgado
Journal:  Pharmaceutics       Date:  2011-08-29       Impact factor: 6.321

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.